All In Biotech

Drug Trial Radar · NCT01461655

Efficacy and the Tolerability of the Sequential Application of Two Marketed Products in Patients With Acne Vulgaris

Exploratory Study Evaluating the Efficacy and the Tolerability of the Sequential Application of Two Marketed Products in Patients With Acne Vulgaris, Using a Split-Face Model

Last checked: Nov 20, 2026Latest source record: Mar 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

40

Actual

Start

Nov 2011

Primary completion

Apr 2012

Study completion May 2012

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
First posted
Oct 28, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Single group
Masking
Single (investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this proof of principle study is to evaluate efficacy and safety of the sequential application of two marketed products for the treatment of acne vulgaris, using the Split-Face model

Conditions

  • Acne Vulgaris

Interventions

  • marketed topical retinoidDrug

    once daily application, 4 weeks

  • marketed topical NSAIDDrug

    once daily application, 4 weeks

  • vehicle gelDrug

    once daily application, 4 weeks

  • marketed topical retinoidDrug

    once daily application, 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage Change in Inflammatory Lesions From Baseline to End of TreatmentTime frame: Baseline to End of treatment (4 weeks)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CPCAD - Centre de Pharmacologie Clinique Appliquée à la Dermatologie

    Nice, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.